January 17-19, 2018
Miami, Florida

The event will be held at the Miami Beach Resort.  

The 2018 PRELIMINARY PROGRAM will be posted at the beginning of December 2017.

The 16th Mild Cognitive Impairment Symposium and Special Topic Workshop (CME/CE accredited) will follow immediately on January 20-21 2018 at the same venue. 

You may review themes, the program and speakers at the MCI website.



Peter Davies received a BSc and a PhD, both in Biochemistry from the University of Leeds, England. He was a post-doctoral fellow in the Department of Pharmacology at the University of Edinburgh, Scotland, before joining the staff of the Medical Research Council Brain Metabolism Unit in Edinburgh in 1974, where he began his research on Alzheimer’s disease.

Dr. Davies’ early work was instrumental in the development of the currently approved drugs for Alzheimer’s disease — Aricept, Exelon and Razodyne. In 1977, he moved to Albert Einstein College of Medicine in the Bronx, NY, where he was a professor in the departments of pathology and neuroscience. Dr. Davies became the Scientific Director of the Litwin/Zucker Center for Research on Alzheimer’s Disease at Northwell Health’s Feinstein Institute for Medical Research in 2006.

For more than 35 years, Dr. Davies’ research has been focused on biochemistry of Alzheimer’s disease. He has published over 250 research papers and has been particularly interested in the development of new treatments and diagnostic tests for Alzheimer’s disease. He has received numerous awards for his research, including the City of New York Liberty Medal, a Lifetime Achievement Award from the International Congress on Alzheimer’s Disease (ICAD) and the first Metropolitan Life Foundation Prize. Dr Davies has also received two MERIT awards from the National Institutes of Health (NIMH, 1989-1999, and NIA 2003-2013).



Dr. Seeley attended medical school at the University of California at San Francisco (UCSF), where he first encountered patients with frontotemporal dementia (FTD) in 1999, during a research elective with Dr. Bruce Miller. He then completed a neurology residency at Harvard Medical School, training at the Massachusetts General and Brigham & Women’s Hospitals. Returning to UCSF for a behavioral neurology fellowship, with Dr. Miller, Dr. Seeley developed expertise in the differential diagnosis and treatment of patients with neurodegenerative disease. He is currently an Associate Professor of Neurology at the UCSF Memory and Aging Center, where he participates in patient evaluation and management.

Dr. Seeley’s research in his Selective Vulnerability Research Laboratory concerns regional vulnerability in dementia, that is, why particular dementias target specific neuronal populations. Dr. Seeley addresses this question through behavioral, functional imaging and neuropathology studies. The goal of his research is to determine what makes brain tissues susceptible or resistant to degeneration, with an eye toward ultimately translating these findings into novel treatment approaches.


Wednesday, January 11, 2017
11:30 amCheck-in
12:30pmWelcome NotesKeith Johnson
Massachusetts General Hospital
12:40SESSION 1
Quantifying Tau and Amyloid PET Signal
Chester Mathis
University of Pittsburgh
Bradley Christian
University of Wisconsin
12:40Evaluating different in vivo measures of tau pathology for use as biomarkersAnne Maass
University of California , Berkeley
12:55Tau Load: a novel method for quantifying subject-specific neuropathologic tau signal from Flortaucipir PET Michael Navitsky
Avid Radiopharmaceuticals
1:10Recovering signal from AV1451 in frontotemporal lobar degeneration with partial volume correctionAdam Martersteck
Northwestern University Feinberg School of Medicine
1:25Unbiased clustering using entorhinal and neocortical tau-PET uptake on [18F]AV-1451 maps onto age and clinical presentation in Alzheimer's diseaseJennifer Whitwell
Mayo Clinic
1:40Nonlinear alignment of multimodal empirical distributions for Level-2 Centiloid transformations
Michael Properzi
Massachusetts General Hospital, Harvard Medical School
2:25Keynote Lecture: Tau Prion Strains: Implications for Imaging Marc Diamond
University of Texas Southwestern
2:55Keynote Discussion
3:10POSTER SESSION 1 and Coffee Break
Novel Tau Tracers
Julie Price
Massachusetts General Hospital
Robert Koeppe
University of Michigan
4:40Effects of [18F]AV-1451 binding in cerebellar gray and extra-cortical areasSuzanne Baker
Lawrence Berkeley National Laboratory
4:55[18F]MK-6240, a novel neurofibrillary tangles PET tracer: Evaluation in healthy subjects and Alzheimer's Disease patientsCyrille Sur
Merck & Co., Inc.
5:10Current efforts to overcome drawbacks of [11C]PBB3 by developing new PBB3 derivatives: first-in-human PET study with [18F]AM-PBB3
Hitoshi Shimada
National Institute of Radiological Sciences
5:25Evaluation of baseline and longitudinal tau burden in Alzheimer’s disease using [18F]GTP1 (Genentech tau probe 1) PET imaging
Sandra Sanabria
Genentech Inc.
5:40Invited Lecture: Molecular Imaging Analysis for Tracer Validation and Clinical TrialsRoger Gunn
Imanova Ltd
6:30-8:30Welcome Reception
Thursday, January 12, 2017
7:00amCheck-in and Breakfast
Neuropathology I: Tau PET Ligand Selectivity and Comparative Studies
William Klunk
University of Pittsburgh
Milos Ikonomovic
University of Pittsburgh
8:00Evaluation of the selectivity of Tau PET radioligand THK5351 in AD brain in vitro and nonhuman primate brain in vivoQi Guo
AbbVie Inc.
8:15Characterizing the “off-target” binding of 18F-THK5351 in Alzheimer’s disease: correlation between ante-mortem and post-mortem findings
Ryuichi Harada
Tohoku University Graduate School of Medicine
8:30In vitro binding properties comparison of the tau PET tracers THK5117, THK5351, PBB3 and T807 in autopsy brain from Alzheimer diseases casesLaetitia Lemoine
Karolinska Institute
8:45An autoradiographic evaluation of THK-5351 compared to AV-1451Melissa Murray
Mayo Clinic
9:30POSTER SESSION 2A and Coffee Break
10:15SESSION 4
Neuropathology II: PET to Autopsy Correlations
Melissa Murray
Mayo Clinic
Teresa Gomez-Isla
Massachusetts General Hospital
10:15Neuropathology and biochemical correlations of [F-18]AV-1451 and [C-11]PiB PET imaging in a subject with Alzheimer's diseaseMilos Ikonomovic
University of Pittsburgh
10:30Neuroimaging-pathologic correlation of [F-18]-AV-1451 in an autopsy confirmed Parkinson's disease caseMarta Marquie-Sayagues
MassGeneral Institute for Neurodegenerative Disease
10:45Multimodal evaluation of 18F-AV-1451 PET in an autopsy-confirmed corticobasal degeneration patientCorey McMillan
Perelman School of Medicine at the University of Pennsylvania
11:25Announcement: Alpha–synuclein Imaging PrizeJamie Eberling
The Michael J. Fox Foundation for Parkinson’s Research
11:30Keynote Lecture: Tau PET for Alzheimer’s Disease: Possible Promise and Pitfalls
Thomas Beach
Banner Sunhealth Research Institute
12:00pmKeynote Discussion
Tau PET: Non-AD Targets
Gil Rabinovici
University of California, San Francisco
Brad Dickerson
Massachusetts General Hospital
1:4518F Flortaucipir binding in choroid plexus: association with race and hippocampus bindingChristopher Lee
Massachusetts General Hospital, Harvard Medical School
2:00[18F]Flortaucipir, aka [18F]AV-1451, Autoradiography Matches Immunofluorescent Staining From AT8 Tau Antibody in Chronic Traumatic Encephalopathy (CTE) Post-Mortem Brain Tissue Sections
Yin-Guo Lin
Avid Radiopharmaceuticals, Inc.
2:15Microscopic neuropathological evaluation of the binding profile of tau selective PET ligands in Alzheimer's disease and primary tauopathiesMelissa Wren
University College London
2:30AV-1451 tau-PET uptake in MAPT mutation carriers varies by tau isoformsDavid Jones
Mayo Clinic
2:4518F-AV-1451 binding in familial frontotemporal lobar degeneration with tau pathologyWilliam Kreisl
Columbia University
3:30POSTER SESSION 2B and Coffee Break
Thresholds and Centiloids
Keith Johnson
Massachusetts General Hospital
Susan Landau
University of California, Berkeley
4:15Defining cut-points for imaging biomarkers used in brain aging and Alzheimer's disease researchClifford Jack
Mayo Clinic
4:30Further adventures in the world of centiloidsRobert Koeppe
University of Michigan
6:30 - 8:30Networking Reception
Friday, January 13, 2017
7:00amCheck-in and Breakfast
Amyloid and Tau PET in Clinical Trials
Bill Jagust
University of California, Berkeley
Susan Resnick
National Institutes of Health
8:00The A4 Study: Preliminary Analyses of Baseline Tau PET Imaging Reisa Sperling
Harvard Medical School
8:15Conversion of aMCI subjects to AD in relation to [18F]flutemetamol Amyloid status, and hippocampal volume in a phase III longitudinal studyDavid Wolk
Perelman School of Medicine at the University of Pennsylvania
8:30Baseline 18F Flortaucipir SUVR, but not amyloid or cognition, predicts cognitive decline over 18 months in Phase 2 trial subjectsMichael Devous, Sr.
Avid Radiopharmaceuticals
8:45PET amyloid and tau imaging in a Phase 3 study of solanezumabMark Mintun
Avid Radiopharmaceuticals
9:30POSTER SESSION 3A and Coffee Break
10:15SESSION 8
Preclinical AD
Reisa Sperling
Harvard Medical School
Elizabeth Mormino
Stanford University
10:15Implementing and testing the new A/T/N classification in AIBL participants combining fluid (CSF) and different Aβ and tau imaging radiotracersVictor Villemagne
University of Melbourne
10:30The Relationship of Elevated Medial Temporal Lobe and Diffuse Brain Tau-PET Signal in Clinically Normal ParticipantsVal Lowe
Mayo Clinic
Prevalence and incidence of amyloid positivity in cognitively normal elderly individualsNeelesh Nadkarni
University of Pittsburgh
11:00Longitudinal tau accumulation is associated with cognitive decline in normal elderlyBernard Hanseeuw
Harvard Medical School
11:15Baseline amyloid burden predicts cognitive decline four years later in healthy adults: The value of a dose-response analysisMichelle Farrell
University of Texas at Dallas
12:00pmKeynote Lecture: Alzheimer’s disease clinical trials: 2017 updateHoward Feldman
University of California, San Diego
12:30Keynote Discussion
Amyloid, Tau, and Neurodegeneration
Clifford Jack
Mayo Clinic
Tammie Benzinger
Washington University at St Louis
2:15Neocortical Tau and hippocampus volume reflect distinct processes in preclinical Alzheimer's diseaseElizabeth Mormino
Stanford University
2:30Do neurodegeneration or amyloid pathology contribute to the relationship between AV-1451 and cognitive symptoms in Alzheimer's disease?Alexandre Bejanin
University of California, San Francisco
2:45Comparing the contributions of tau and neurodegenerative biomarkers to cognitive declineSusan Landau
University of California, Berkeley
3:00Differential genotypic variance in PET and CSF measures of amyloid burden: Findings from the DIAN StudyJasmeer Chhatwal
Massachusetts General Hospital
3:15Relationships between AV1451-PET and CSF biomarkers in a heterogeneous clinical sampleRenaud La Joie, University of California, San Francisco
4:00POSTER SESSION 3B and Coffee Break
4:45Awards Ceremony
4:50SESSION 10
Amyloid and Tau PET in Distinct Populations
Trey Hedden
Massachusetts General Hospital
Charles de Carli
University of California, Davis
4:50Association of regional FDG hypometabolism with age, amyloid, tau, and cardiac and metabolic conditions along the AD continuumPrashanthi Vemuri, Mayo Clinic
5:0518F-AV1451 PET in patients with subcortical vascular cognitive impairmentSang Won Seo, Sungkyunkwan University School of
5:20White matter hyperintensities and brain amyloid deposition: The ARIC-PET StudyRebecca Gottesman
Johns Hopkins University
5:35Association of amyloid-beta plaque accumulation and glucose hypometabolism in Down syndrome demonstrates pattern associated with Alzheimer's diseasePatrick Lao, University of Wisconsin
6:20Closing NotesKeith Johnson, Massachusetts General Hospital